Bruker has introduced a new nuclear magnetic resonance (NMR)-based molecular phenomics clinical research tool, called PhenoRisk PACS RuO, for the assessment of risk and multi-organ damage in ‘Long Covid’ patients.
The research-use-only test enables risk screening for Post-acute Covid syndrome (PACS), which is commonly known as Long Covid syndrome.
It also enables quantitative multiplexed testing for the early detection of clinically well-characterised risk markers.
The tool uses a multiplexed combination of biomarkers, which were discovered at the Australian National Phenome Center (ANPC) at Murdoch University in Perth.
PhenoRisk PACS RuO is designed for research into early-stage risk factors, longitudinal recovery monitoring and potential damage of secondary organs in cardiovascular disease, kidney dysfunction and inflammation, and type II diabetes.
The test includes an Avance IVDr NMR spectroscopy system that can evaluate many biological mechanisms of action simultaneously in a blood test collected from Long Covid patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Furthermore, it characterises SARS-CoV-2 pathobiology’s metabolic and proteomic biomarkers, even in cases of asymptomatic acute Covid.
This enables the evaluation of multi-organ risk, recovery and therapeutic research in several dysfunctions related to Long Covid.
By studying Covid-triggered pheno-conversion, the PhenoRisk PACS RuO test can differentiate PACS patients from healthy or completely recovered individuals.
Additionally, the test can measure composite signals for glycoproteins and phospholipids’ groups, which help to indicate inflammation and cardiovascular disease risks, as well as a new NMR biomarker known as Supramolecular Phospholipid Composite (SPC).
Bruker BioSpin applied, industrial and clinical division president Dr Iris Mangelschots said: “We are very excited to provide this multi-organ PACS risk screen to the clinical and pharmaceutical research community, after the preliminary validation by our partners in the International Covid-19 Research Network.
“We believe that PhenoRisk PACS RuO could make a significant contribution in research to combat the effects of Long Covid.”